Innate Pharma secures $30M equity raise and $75M SOBI upfront payment, advancing IPH 4502 and lacutamab while positioning for key PACIFIC-9 readout.

Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma to run the TELLOMAK-3 Phase 3 trial for lacutamab in cutaneous T cell lymphoma. See our latest analysis for Swedish Orphan Biovitrum. The lacutamab agreement lands after a softer month for Swedish Orphan Biovitrum’s share price, which is down about 3.4% over 30 days. However, the year-to-date share price return of 33.3% and 1-year total...

Innate Pharma (NASDAQ:IPHA) said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio. Chief Executive Officer Jonathan Dic

Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare subset of CTCL.

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung

Analysts are now discussing an updated €8 price target for Innate Pharma, while the fair value estimate sits at €6.10 with no change to the underlying model. This shift is being framed around what both bullish and bearish voices see in the 2026 catalyst cluster, including funding needs and how upcoming oncology readouts could influence sentiment. As you read on, you will see how these moving pieces fit together and what to watch as the story develops. Stay updated as the Fair Value for Innate...

Innate Pharma SA (IPHA) progresses with key trials and partnerships while navigating financial hurdles and revenue drops.

Innate Pharma (NASDAQ:IPHA) outlined progress across its prioritized oncology pipeline and reviewed full-year 2025 financial results, emphasizing a streamlined strategy centered on three clinical programs: lacutamab, IPH4502, and monalizumab. Management also highlighted an AstraZeneca-partnered prog

Innate Pharma (IPHA) said Monday that the US Food and Drug Administration completed a review of its

After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Innate Pharma’s consensus analyst price target has recently jumped from €4.34 to €4.93. This marks a significant shift in expectations for the stock. This change comes amid a period of strategic transition, with analysts debating the company’s new priorities and ongoing risks. Readers interested in how analyst sentiment may keep evolving should continue following updates to stay ahead of future narrative shifts. What Wall Street Has Been Saying 🐂 Bullish Takeaways Several analysts highlight...